WallStreetZenWallStreetZen

NYSE: DGX
Quest Diagnostics Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Quest Diagnostics earnings were $1.1B for the trailing 12 months ending Jun 30, 2026, with 12.6% growth year over year. The latest DGX earnings report on Jun 30, 2026 announced Q2 2026 earnings of $320.0M, up 27% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, DGX reported annual earnings of $992.0M, with 13.9% growth.

DGX past earnings growth

How has DGX's earnings growth performed historically?

Company
12.63%
Industry
11.21%
Market
87.41%
DGX's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
DGX's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
DGX's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

DGX earnings history

Current Revenue
$11.6B
Current Earnings
$1.1B
Current Profit Margin
9.2%
DGX's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

DGX Return on Equity

Current Company
14.5%
Current Industry
-33.4%
Current Market
30.1%
DGX's Return on Equity (14.5%)... subscribe to Premium to read more.
High Return on Equity Performance

DGX Return on Assets

Current Company
6.4%
Current Industry
6.5%
DGX is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when DGX announces earnings.

DGX Return on Capital Employed

Current Company
10.81%
Current Industry
13.3%
DGX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

DGX vs Diagnostic & Research Stocks

TickerEBITDAEarningsY/Y EarningsEPS
DGX$2.22B$1.06B-10.97%$9.54
LH$2.36B$1.00B-16.25%$12.17
ILMN$1.39B$825.00M+0.53%$5.40
MTD$1.30B$905.61M+8.01%$44.47
GH-$411.19M-$453.44MN/A-$3.49
View Top Diagnostic & Research Stocks

Quest Diagnostics Earnings Reports & History FAQ

What were Quest Diagnostics's earnings last quarter?

On DGX's earnings call on Jul 23, 2026, Quest Diagnostics (NYSE: DGX) reported Q2 2026 earnings per share (EPS) of $2.88, up 14.74% year over year. Total DGX earnings for the quarter were $320.00 million. In the same quarter last year, Quest Diagnostics's earnings per share (EPS) was $2.51.

If you're new to stock investing, here's how to buy Quest Diagnostics stock.

Is Quest Diagnostics profitable or losing money?

As of the last Quest Diagnostics earnings report, Quest Diagnostics is currently profitable. Quest Diagnostics's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $1.06 billion, a 11.79% increase year over year.

What was DGX's earnings growth in the past year?

As of Quest Diagnostics's earnings date in Jul 23, 2026, Quest Diagnostics's earnings has grown 12.63% year over year. This is 1.42 percentage points higher than the US Diagnostics & Research industry earnings growth rate of 11.21%. DGX earnings in the past year totalled $1.06 billion.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.